{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003293","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.412849+00:00","generated_at":"2026-06-27T00:06:14.634931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyne Therapeutics reports FY2021 net loss $149.3M; cash to H2 2024; pipeline milestones outlined","bullets":["Net loss of $149.3M for 2021 ($2.93/share) vs $59.4M in 2020; R&D spend $121.3M.","Cash, equivalents and securities $376.6M at Dec 31, 2021; cash runway into second half 2024.","FDA response for DYNE-251 IND in DMD expected Q2 2022; patient dosing in Phase 1/2 planned mid-2022.","Regulatory filings for DYNE-101 in DM1 in multiple countries planned Q2 2022 with mid-2022 trial start.","IND for DYNE-301 in FSHD expected in second half of 2022; board appointment of Carlo Incerti, M.D."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003293","json":"https://secwatch.observer/filing/0000950170-22-003293.json","markdown":"https://secwatch.observer/filing/0000950170-22-003293.md","text":"https://secwatch.observer/filing/0000950170-22-003293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022003293/0000950170-22-003293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022003293/dyn-20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:06:14.634931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}